+25 year(s) experience
Rachel began her time at Citeline as a drug specialist, managing Trialtrove’s auxiliary drug database. Since then, she has worked as an analyst specializing in autoimmune/inflammation drugs, immuno-oncology/immunotherapy, pharmacogenomic biomarkers, companion diagnostics, repurposing of drugs and regulatory approval pathways.
Before joining us, Rachel was a scientist in genetic and molecular toxicology for a global contract research organization. She also worked as an adjunct professor at two community colleges and as a research fellow in vascular biology, pharmacology and cancer biology.
Pharmaprojects: 医薬品開発パイプラインのデータベース, Biomedtracker: 開発中医薬品をFD...
The field of epigenetics is rapidly expanding and as interest continues to grow, epigenetics has become an increasingly promising area for research.
Pharmaprojects: 医薬品開発パイプラインのデータベース, Trialtrove: 医療用医薬品の臨床試験情...
Plenty of excitement has been generated recently in the immuno-oncology sphere by the accelerated approvals in May 2016 by the FDA for Bristol-Myers Squibb’s PD-1 antagonist, nivolumab (Opdivo), in relapsed/refractory classical Hodgkin’s lymphoma and for Genentech’s PD-L1 antagonist, atezolizumab (Tecentriq), in relapsed/refractory, advanced or metastatic urothelial carcinoma.